Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 3 Effects of tolvaptan relative to placebo on body weight at 24 h (the primary end point of the study) and at discharge in the Acute and Chronic Therapeutic Impact of a Vasopressin (ACTIV) trial. *p < 0.05 vs. placebo. Adapted from reference 55. White bars = placebo; black bars = tolvaptan 0 mg; dotted bars = tolvaptan 60 mg; grey bars = tolvaptan 90 mg.
|
